March 31 (Reuters) - Mesoblast Ltd MSB.AX :
* Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast'S phase 3 chronic heart failure trial
* Says interim analysis dataset has been locked and will be analyzed and reviewed by trial's independent statisticians
* Mesoblast Ltd - throughout review process, co to remain blinded to individual treatment allocation as well as grouped safety and efficacy data
* Mesoblast Ltd - IDMC will review and interpret results of interim analysis and provide recommendations shortly Source text for Eikon: ID:nGNXNSFTGa Further company coverage: MSB.AX